/
NERV
$5.43+$1.06 (+24.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$203.6M
47M shares
52-week range
$1.57 – $12.46
35% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.29%
Moderate
Price (6 mo)
Loading chart…
Change$-13.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $41.2M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $17.5K | $161.5K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$17.5K | −$162.0K | $41.2M | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | 100.0% | — | — | — | — | — |
| R&D | $34.9M | $58.1M | $22.0M | $32.0M | $14.6M | $12.7M | $11.9M | $5.8M |
| Operating income | −$51.7M | −$75.9M | $1.8M | −$45.4M | −$25.2M | −$23.1M | −$21.8M | −$15.1M |
| EBITDA | −$50.0M | −$74.3M | $2.1M | −$45.3M | −$24.7M | −$21.7M | $6.0M | −$293.4M |
| Net income | −$50.2M | −$72.2M | $1.9M | −$49.9M | −$32.1M | −$30.0M | $1.4M | −$293.4M |
| Net margin | — | — | 4.7% | — | — | — | — | — |
| EPS (diluted) | -10.35 | -14.80 | 0.38 | -9.35 | -6.01 | -4.61 | 0.19 | -34.67 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-3.54 | $-3.54–$-3.54 | 1 |
| 2027 | $56M | $-0.69 | $-0.69–$-0.69 | 1 |
| 2028 | $13M | $-0.83 | $-0.83–$-0.83 | 1 |
| 2029 | $20M | $-0.42 | $-0.42–$-0.42 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.98
Price
$5.43
Implied downside
-64%
Peer comparison
Minerva Neurosciences, Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
www.minervaneurosciences.com- Employees
- 7
- IPO / List date
- Jul 1, 2014
- HQ
- BURLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds NERV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 89,700 | $540.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-06-21 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded NERV yet.
